Iodine oral

Drug Profile

Iodine oral

Alternative Names: BPX 03; IoGen

Latest Information Update: 20 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Symbollon Pharmaceuticals
  • Developer BioPharmX Corporation; Jacobson Resonance Enterprises; Symbollon Pharmaceuticals
  • Class Disinfectants; Halogens
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Breast pain
  • Discontinued Fibrocystic breast disorders; Solid tumours

Most Recent Events

  • 14 Nov 2007 Phase III development in fibrocystic breast disorders is ongoing
  • 04 Jan 2007 Gardant Pharmaceuticals has been acquired by Switch Pharma
  • 14 Jun 2005 Symbollon Pharmaceuticals has initiated enrolment in a pivotal phase III trial for Fibrocystic breast disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top